CRISPR-Cas9: A revolutionary gene-editing technology that transforms biology and medicine
Speaker: Emmanuelle Charpentier, Ph.D., Director of Max Planck Institute of Infection Biology
Since scientists discovered the DNA targeting mechanism of the bacterial CRISPR-Cas9 system and reduced it into an RNA-programmable gene editing technology, the system has been applied to a wide range of projects from basic science to drug development. It has helped to optimize crops and build animal models of disease. Tool and kit service companies offer CRISPR-Cas9-related products and at least three biotechnology companies have been founded during the past years to develop the technology for the treatment of serious human genetic disorders. CRISPR-Cas9 is poised to maintain a prominent role in the life sciences for years to come. Emmanuelle Charpentier, one of the first scientists to harness the technology, explores its potential applications and limitations.
Music: Emmanuel Ceysson, Principal Harp of the Metropolitan Opera Orchestra. Presented by the Chamber Music Society of Palm Beach
Join us for the entire 2017 series!
- Iain Couzin, PhD, Director, Max Planck Institute of Ornithology
- Samuel M. Young, Jr., PhD, Research Group Leader of the Max Planck Florida Institute for Neuroscience